Ad is loading...
ADNRX vs PAMCX
ADNRX vs PAMCX Comparison
Open Charts ADNRX vs PAMCX
American Beacon ARK Transfmt Innov R6
Price$16.27
Change-$0.03 (-0.18%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth Adv
Price$95.02
Change-$0.05 (-0.05%)
VolumeN/A
CapitalizationN/A
ADNRX vs PAMCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
ADNRX vs. PAMCX commentary
Dec 25, 2024
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADNRX is a Hold and PAMCX is a Buy.
FUNDAMENTALS
Fundamentals
PAMCX has more cash in the bank: 30.6B vs. ADNRX (217M). ADNRX (0.00) and PAMCX (0.00) have matching dividends . ADNRX was incepted earlier than PAMCX: ADNRX (4 years) vs PAMCX (25 years). ADNRX is a more actively managed with annual turnover of: 33.00 vs. PAMCX (21.70). ADNRX has a lower initial minimum investment than PAMCX: ADNRX (0) vs PAMCX (2500). ADNRX annual gain was more profitable for investors over the last year : 12.21 vs. PAMCX (0.34).
| ADNRX | PAMCX | ADNRX / PAMCX | |
| Total Expense Ratio | N/A | N/A | - |
| Annual Report Gross Expense Ratio | N/A | N/A | - |
| Fund Existence | 4 years | 25 years | - |
| Gain YTD | 13.301 | 0.011 | 126,441% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2500 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 217M | 30.6B | 1% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 12.21 | 0.34 | 3,612% |
| Returns for 3 years | -43.19 | -14.41 | 300% |
| Returns for 5 years | N/A | 3.09 | - |
| Returns for 10 years | N/A | 27.61 | - |